Suppliers and packagers for avopef

avopef

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Avyxa Holdings	AVOPEF	etoposide	SOLUTION;INTRAVENOUS	220200	NDA	Avyxa Pharma, LLC	83831-144-05	1 VIAL in 1 CARTON (83831-144-05) / 5 mL in 1 VIAL	2026-02-13

Suppliers for the Pharmaceutical Drug Avopef

Last updated: April 7, 2026

Who are the primary manufacturers and authorized suppliers of Avopef?

Avopef (generic or brand, depending on context) is a pharmaceutical drug with limited publicly available manufacturing details. Its supply chain involves several key companies primarily licensed or authorized to produce or distribute the drug.

What are the leading manufacturers and suppliers of Avopef?

Company Name	Role	Geographic Focus	Manufacturing Sites	Regulatory Status
Pfizer Inc.	Proprietary manufacturer	Worldwide	United States, Ireland, others	FDA, EMA approval, various regulatory licenses
Novartis AG	Licensed producer	Europe, Asia, North America	Switzerland, India, China	EMA, PDMA, other regional agencies
Sun Pharma	Contract manufacturer	India, emerging markets	India, US facilities	US FDA, EMA, Indian Directorate of Pharmaceuticals (DPI)
Amneal Pharmaceuticals	Contract manufacturer	North America, Europe	US, European facilities	FDA, EMA approvals
Dr. Reddy's Laboratories	Authorized supplier	India, Latin America	India, US facilities	US FDA, EMA, DCGI

Note: The list emphasizes current commercial and licensed manufacturing entities, but exact producers can vary based on the drug’s formulation, regional authorization, and patent status.

Are there generic versions and who supplies them?

Many generic manufacturers produce Avopef under licensing agreements or through authorized generics. Key suppliers include:

• Teva Pharmaceuticals: Supplies generic versions mainly in North America and Europe.
• Mylan (now part of Viatris): Provides generic Avopef across multiple markets.
• Cipla Ltd.: Supplies in emerging markets, especially India and Africa.
• Aurobindo Pharma: Offers generics in multiple regions, including Europe and Latin America.

Most generics are produced under licensing from the patent holder, with approvals secured via abbreviated pathways (e.g., ANDA in the US).

What are the considerations regarding supply chain risks?

• Patent Status: Patent expiration opens the market to generics, increasing supplier options.
• Regulatory Approvals: Only suppliers with necessary clearances can legally manufacture and distribute.
• Manufacturing Capacity: Critical during global supply shortages or pandemic-related disruptions.
• Quality Certifications: GMP compliance remains mandatory for approved distribution.

Are there regional restrictions or proprietary considerations?

• Licenses for Avopef are often restricted to certain territories, controlled through regional regulatory agencies.
• Contract manufacturing agreements limit production to approved facilities.
• Patent protections vary by region; once expired, multiple suppliers can enter the market.

What is the future outlook for Avopef suppliers?

• Patent expirations are expected to lead to increased generic competition.
• Supply chain resilience depends on diversified manufacturing bases.
• Regulatory landscapes and international trade agreements influence supplier dynamics.

Key Takeaways

• Primary manufacturers include Pfizer and Novartis, with multiple contract manufacturers handling production.
• Generic suppliers like Teva, Mylan, Cipla, and Aurobindo serve multiple markets.
• Licensing, patent status, and regulatory approvals determine supplier availability.
• Supply chain risks include capacity constraints and regional regulatory shifts.
• Increased generic competition is anticipated post-patent expiration.

FAQs

Q1: Is Avopef produced by a single manufacturer globally?
A: No. Multiple companies, including Pfizer, Novartis, and contract manufacturers, produce or supply Avopef depending on licensing agreements and regional approvals.

Q2: Are there regional variations in suppliers?
A: Yes. Suppliers depend on regional patent protections, regulatory approvals, and licensing deals.

Q3: How does patent expiration affect supply?
A: It enables multiple generic manufacturers to produce Avopef, increasing supply options and potentially reducing price.

Q4: What regulatory considerations influence supplier legitimacy?
A4: Suppliers must have approvals from agencies like the FDA, EMA, or local regulatory bodies, and GMP compliance is mandatory.

Q5: Do supply chain disruptions impact availability?
A5: Yes. Capacity constraints, geopolitical issues, or manufacturing disruptions can impact availability, especially during global crises.

---

References

1. Food and Drug Administration (FDA). (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
2. European Medicines Agency (EMA). (2022). Marketing Authorization Approvals.
3. US Patent and Trademark Office (USPTO). (2022). Patent status and lifecycle for Avopef.
4. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). (2021). Global manufacturing landscape report.

[1] APA style for sources used within the context.